Mountain Valley MD Holdings Inc.

CNSX:MVMD Stock Report

Market Cap: CA$10.6m

Mountain Valley MD Holdings Past Earnings Performance

Past criteria checks 0/6

Mountain Valley MD Holdings has been growing earnings at an average annual rate of 28.8%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 18% per year.

Key information

28.8%

Earnings growth rate

41.0%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth rate18.0%
Return on equity-82.9%
Net Margin-8,700.0%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

We're Not Very Worried About Mountain Valley MD Holdings' (CSE:MVMD) Cash Burn Rate

Jan 09
We're Not Very Worried About Mountain Valley MD Holdings' (CSE:MVMD) Cash Burn Rate

Is Mountain Valley MD Holdings (CSE:MVMD) In A Good Position To Invest In Growth?

Jul 14
Is Mountain Valley MD Holdings (CSE:MVMD) In A Good Position To Invest In Growth?

Revenue & Expenses Breakdown

How Mountain Valley MD Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:MVMD Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-830
31 Mar 240-830
31 Dec 230-731
30 Sep 230-431
30 Jun 230-631
31 Mar 230-741
31 Dec 220-742
30 Sep 220-962
30 Jun 220-972
31 Mar 220-1072
31 Dec 210-1483
30 Sep 210-1262
30 Jun 210-1042
31 Mar 210-831
31 Dec 200-2030
30 Sep 200-1930
30 Jun 200-1930
31 Mar 200-1930

Quality Earnings: MVMD is currently unprofitable.

Growing Profit Margin: MVMD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MVMD is unprofitable, but has reduced losses over the past 5 years at a rate of 28.8% per year.

Accelerating Growth: Unable to compare MVMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MVMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-44%).


Return on Equity

High ROE: MVMD has a negative Return on Equity (-82.88%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies